| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/09/2009 | US20090093617 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 04/09/2009 | US20090093549 Aqueous Pharmaceutical Compositions Of 2,6-Diisopropylphenol (Propofol) And Their Uses |
| 04/09/2009 | US20090093522 Freeze-dried pantoprazole preparation and pantoprazole injection |
| 04/09/2009 | US20090093487 Compositions for topical application having androgenic actions |
| 04/09/2009 | US20090092739 Method of dip-coating dosage forms |
| 04/09/2009 | US20090092727 Water-dispersible phytosterol-surfactant conglomerate particles |
| 04/09/2009 | US20090092677 Multi-component particles for injection and processes for forming the same |
| 04/09/2009 | US20090092676 Cross-linked polymer particles |
| 04/09/2009 | US20090092675 Compositions containing multiple polymers and particles made using the compositions |
| 04/09/2009 | US20090092674 Flowable wound matrix and its preparation and use |
| 04/09/2009 | US20090092672 Orally disintegrating tablet compositions of lamotrigine |
| 04/09/2009 | US20090092671 Cerium Oxide Nanoparticles for Treatment and Prevention of Alzheimer's Disease, Parkinson's Disease, and Disorders Associated with Free Radical Production and/or Mitochondrial Dysfunction |
| 04/09/2009 | US20090092670 Long acting dual release product containing carbinoxamine and pseudoephedrine |
| 04/09/2009 | US20090092669 Stable imatinib compositions |
| 04/09/2009 | US20090092668 Acetaminophen formulation for joint pain relief |
| 04/09/2009 | US20090092667 Method for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis with (-)-Nilvadipine Enantiomer |
| 04/09/2009 | US20090092666 Vaccines with enhanced immune response and methods for their preparation |
| 04/09/2009 | US20090092665 OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR mTOR INHIBITORS |
| 04/09/2009 | US20090092664 Polymer-metal chelator conjugates and uses thereof |
| 04/09/2009 | US20090092663 Tumor-targeted drug delivery systems and uses thereof |
| 04/09/2009 | US20090092662 Liposome formulations of boronic acid compounds |
| 04/09/2009 | US20090092661 Liposome compositions for in vivo administration of boronic acid compounds |
| 04/09/2009 | US20090092660 Methods and compositions for needleless delivery of particles |
| 04/09/2009 | US20090092659 containing protonated/acidified nucleic acids that are bactericidal; wound sealant, surgical drape , skin substitute |
| 04/09/2009 | US20090092658 Novel formulations of proton pump inhibitors and methods of using these formulations |
| 04/09/2009 | US20090092656 Method of treating atrophic vaginitis |
| 04/09/2009 | US20090092655 Novel prepolymerizable surface active monomers with both fluorine-containing groups and hydrophilic groups |
| 04/09/2009 | US20090092653 Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
| 04/09/2009 | US20090092652 Method for the inhibition of angiogenesis or cancer using protective antigen related molecules |
| 04/09/2009 | US20090092650 Sustained Delivery Formulations of Octreotide Compounds |
| 04/09/2009 | US20090092648 Antimicrobial polymer compositions and the use thereof |
| 04/09/2009 | US20090092646 Effigy and Compound to Affect Bird Behavior |
| 04/09/2009 | US20090092645 Radiation Method for Fabrication of Nano-sized Compound Antibacterial Fabric Textile |
| 04/09/2009 | US20090092642 Skin and/or Hair Products, Containing Compounds With an Isoprenoid Structure |
| 04/09/2009 | US20090092559 Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant |
| 04/09/2009 | US20090092558 6-Hydroxy-8-{1-hydroxy-2-[2-(p-alkoxy- or carboxyalkoxyphenyl)-1,1-dimethylethylamino]ethyl}4H-benzo[1,4]oxazin-3-ones, e.g., 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyacetic acid)-1,1-dimethylethylamino]- ethyl}-4H-benzo[1,4]oxazin-3-one; betamimetics |
| 04/09/2009 | US20090092557 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use |
| 04/09/2009 | US20090092556 Azeotrope-like compositions of difluoromethane and trifluoroiodomethane |
| 04/09/2009 | US20090092548 Methods And Compounds For Targeting Tissues |
| 04/09/2009 | DE59303759C5 Wirkstoff-enthaltende festkörper mit einem gerüst aus hydrophilen makromolekülen und verfahren zu ihrer herstellung Drug-containing solid having a backbone of hydrophilic macromolecules and processes for their preparation |
| 04/09/2009 | DE4021517B4 Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide Formulations with delayed release of water-soluble peptides |
| 04/09/2009 | CA2708316A1 Method for producing stable powder compositions |
| 04/09/2009 | CA2703501A1 Orodispersible tablets |
| 04/09/2009 | CA2701721A1 Ophthalmic compositions based on tamarind seed polysaccharide and hyaluronic acid |
| 04/09/2009 | CA2701719A1 Dry powders of cellular material |
| 04/09/2009 | CA2701605A1 Granule, tablet and methods for producing the same |
| 04/09/2009 | CA2701556A1 Mechanical protective layer for solid dosage forms |
| 04/09/2009 | CA2701470A1 Sustained delivery of compstatin analogs from gels |
| 04/09/2009 | CA2701377A1 Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof |
| 04/09/2009 | CA2701291A1 Dendrimers for sustained release of compounds |
| 04/09/2009 | CA2701023A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
| 04/09/2009 | CA2700944A1 Hot melt-filled soft capsules |
| 04/09/2009 | CA2698330A1 Galenical formulations of organic compounds |
| 04/08/2009 | EP2044959A1 In-situ gelling drug delivery system |
| 04/08/2009 | EP2044944A1 Nootropic medicinal agent |
| 04/08/2009 | EP2044941A1 Multiple-phase formulation of drospirenone and estradiol as a contraceptive |
| 04/08/2009 | EP2044934A1 Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof |
| 04/08/2009 | EP2044933A1 Multi particulate matrix system containing galantamine |
| 04/08/2009 | EP2044932A1 Mechanical protective layer for solid dosage forms |
| 04/08/2009 | EP2044931A2 Pharmaceutical compositions based on porous zeolites as release means of pharmacologically active molecules and relative use |
| 04/08/2009 | EP2044930A1 Composition for controlling lipase catalyzed reactions |
| 04/08/2009 | EP2044929A1 Oral fast distintegrating tablets |
| 04/08/2009 | EP2044189A2 Multilayer tablet having a disintegration layer |
| 04/08/2009 | EP2044132A1 Composition |
| 04/08/2009 | EP2043955A1 Metal oxide hydrogels and hydrosols, their preparation and use |
| 04/08/2009 | EP2043670A1 Fermented plant extracts, methods of production and uses |
| 04/08/2009 | EP2043663A1 Topical treatment of warts |
| 04/08/2009 | EP2043657A2 Use of stilbene derivatives for treatment and prevention of aquatic mold infections |
| 04/08/2009 | EP2043647A2 Controlled release formulations and associated methods |
| 04/08/2009 | EP2043627A2 Iron(ii)-containing treatments for hyperphosphatemia |
| 04/08/2009 | EP2043623A2 Nanoparticulate formulations of modafinil |
| 04/08/2009 | EP2043619A2 Chewable tablet containing phenylephrine |
| 04/08/2009 | EP2043618A1 Pharmaceutical formulation comprising donepezil |
| 04/08/2009 | EP2043617A2 Analyte monitoring and therapy management system and methods therefor |
| 04/08/2009 | EP2043615A2 Pharmaceutical compositions comprising levetiracetam |
| 04/08/2009 | EP2043614A2 Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient |
| 04/08/2009 | EP2043613A1 Solid form |
| 04/08/2009 | EP2043612A1 A stable olanzapine formulation with antioxidants |
| 04/08/2009 | EP2043611A2 Metal-containing formulations and methods of use |
| 04/08/2009 | EP2043610A1 Drying of drug-containing particles |
| 04/08/2009 | EP2043609A2 Pellet formulation comprising colloidal silicon dioxide |
| 04/08/2009 | EP2043608A1 Powders for reconstitution |
| 04/08/2009 | EP2043607A2 Process for the preparation of micronized valsartan |
| 04/08/2009 | EP2043606A2 Nanoparticulate kinase inhibitor formulations |
| 04/08/2009 | EP2043605A1 Injectable slow-release formulation of active ingredients, method for the preparation thereof |
| 04/08/2009 | EP2043604A2 Topical compositions |
| 04/08/2009 | EP2043603A2 Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
| 04/08/2009 | EP2043602A2 Cyclosporin compositions |
| 04/08/2009 | EP2043601A1 Aqueous gel formulation and method for inducing topical anesthesia |
| 04/08/2009 | EP2043600A2 Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic |
| 04/08/2009 | EP2043599A1 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| 04/08/2009 | EP2043598A1 Extended release perforated tablet |
| 04/08/2009 | EP2043590A1 Barrier film-forming germicidal compostition for controlling mastitis |
| 04/08/2009 | EP2043456A1 Products containing smart foam and method of making |
| 04/08/2009 | EP1940366B1 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability |
| 04/08/2009 | EP1896056A4 Reinforced collagen scaffold |
| 04/08/2009 | EP1888013B1 Bioresorbable fillers constituted by phospholipid liposomes and hyaluronic acid and/or the derivatives thereof |
| 04/08/2009 | EP1753803B1 Polypeptides with the capacity to entrap drugs and release them in a controlled way |
| 04/08/2009 | EP1673065B1 Microemulsions of retinoids, and pharmaceutical compositions containing them |
| 04/08/2009 | EP1594499B1 Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer |